203 related articles for article (PubMed ID: 10730196)
1. Cisplatin.
Trimmer EE; Essigmann JM
Essays Biochem; 1999; 34():191-211. PubMed ID: 10730196
[TBL] [Abstract][Full Text] [Related]
2. Recognition of cisplatin adducts by cellular proteins.
Kartalou M; Essigmann JM
Mutat Res; 2001 Jul; 478(1-2):1-21. PubMed ID: 11406166
[TBL] [Abstract][Full Text] [Related]
3. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin.
Mello JA; Acharya S; Fishel R; Essigmann JM
Chem Biol; 1996 Jul; 3(7):579-89. PubMed ID: 8807890
[TBL] [Abstract][Full Text] [Related]
4. Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids.
Lippert B
Met Ions Biol Syst; 1996; 33():105-41. PubMed ID: 8742842
[TBL] [Abstract][Full Text] [Related]
5. Recognition and repair of DNA-cisplatin adducts.
Woźniak K; Błasiak J
Acta Biochim Pol; 2002; 49(3):583-96. PubMed ID: 12422229
[TBL] [Abstract][Full Text] [Related]
6. Ultraviolet irradiation produces cytotoxic synergy and increased DNA interstrand crosslinking with cis- and trans-diamminedichloroplatinum(II).
Swinnen LJ; Fisher SG; Erickson LC
Carcinogenesis; 1989 Aug; 10(8):1465-70. PubMed ID: 2752520
[TBL] [Abstract][Full Text] [Related]
7. Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells.
Zhu G; Myint M; Ang WH; Song L; Lippard SJ
Cancer Res; 2012 Feb; 72(3):790-800. PubMed ID: 22180496
[TBL] [Abstract][Full Text] [Related]
8. Recognition of major DNA adducts of enantiomeric cisplatin analogs by HMG box proteins and nucleotide excision repair of these adducts.
Malina J; Kasparkova J; Natile G; Brabec V
Chem Biol; 2002 May; 9(5):629-38. PubMed ID: 12031669
[TBL] [Abstract][Full Text] [Related]
9. DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo.
Mello JA; Lippard SJ; Essigmann JM
Biochemistry; 1995 Nov; 34(45):14783-91. PubMed ID: 7578087
[TBL] [Abstract][Full Text] [Related]
10. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.
Trimmer EE; Zamble DB; Lippard SJ; Essigmann JM
Biochemistry; 1998 Jan; 37(1):352-62. PubMed ID: 9425057
[TBL] [Abstract][Full Text] [Related]
11. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
12. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex.
Mlcouskova J; Malina J; Novohradsky V; Kasparkova J; Komeda S; Brabec V
Biochim Biophys Acta; 2012 Oct; 1820(10):1502-11. PubMed ID: 22683702
[TBL] [Abstract][Full Text] [Related]
13. Different affinity of nuclear factor-kappa B proteins to DNA modified by antitumor cisplatin and its clinically ineffective trans isomer.
Kasparkova J; Thibault T; Kostrhunova H; Stepankova J; Vojtiskova M; Muchova T; Midoux P; Malinge JM; Brabec V
FEBS J; 2014 Mar; 281(5):1393-1408. PubMed ID: 24418212
[TBL] [Abstract][Full Text] [Related]
14. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.
Kasparkova J; Novakova O; Farrell N; Brabec V
Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292
[TBL] [Abstract][Full Text] [Related]
15. Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines.
Hill BT; Shellard SA; Fichtinger-Schepman AM; Schmoll HJ; Harstrick A
Anticancer Drugs; 1994 Jun; 5(3):321-8. PubMed ID: 7919457
[TBL] [Abstract][Full Text] [Related]
16. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
17. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
18. Conformation, protein recognition and repair of DNA interstrand and intrastrand cross-links of antitumor trans-[PtCl2(NH3)(thiazole)].
Marini V; Christofis P; Novakova O; Kasparkova J; Farrell N; Brabec V
Nucleic Acids Res; 2005; 33(18):5819-28. PubMed ID: 16237123
[TBL] [Abstract][Full Text] [Related]
19. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins.
Ohndorf UM; Rould MA; He Q; Pabo CO; Lippard SJ
Nature; 1999 Jun; 399(6737):708-12. PubMed ID: 10385126
[TBL] [Abstract][Full Text] [Related]
20. Repair of cisplatin-induced DNA interstrand crosslinks by a replication-independent pathway involving transcription-coupled repair and translesion synthesis.
Enoiu M; Jiricny J; Schärer OD
Nucleic Acids Res; 2012 Oct; 40(18):8953-64. PubMed ID: 22810206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
